VivoSeq
Oncology

Adrenocortical Carcinoma

0

Pipeline Programs↗

6

Active Trials↗

5

Companies Involved↗

Adrenocortical Carcinoma is an early-stage landscape with 0 programs across 5 companies. The most active players are Spanish Oncology Genito-Urinary Group, Corcept Therapeutics, Millendo Therapeutics SAS.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Spanish Oncology Genito-Urinary Group

0 programs

PreclinicalC

Corcept Therapeutics

0 programs

PreclinicalM

Millendo Therapeutics SAS

0 programs

PreclinicalAstellas logo

Astellas

0 programs

PreclinicalA

Arbutus Biopharma Corporation

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

24

clinical trials

Completed14 · 58%
Recruiting5 · 21%
Unknown status2 · 8%
Active, not recruiting1 · 4%
Withdrawn1 · 4%
Terminated1 · 4%

Clinical Trials

Trial Activity

24 trials

Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.
Recruiting·MMaria Sklodowska-Curie National Research Institute of Oncology·Phase 2·NCT05563467·24 enrolled
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06066333·12 enrolled
Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)
Recruiting·AAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia·Phase 2·NCT05913427·80 enrolled
Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
Recruiting·WWest China Hospital·Phase 2·NCT04318730·21 enrolled
A Phase I Dose-escalation Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06487481·32 enrolled
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02673333·39 enrolled
Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma
Completed·—·Phase 2·NCT00324012·19 enrolled
A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection
Completed·National Cancer Institute (NCI)·Phase 2·NCT00001339·42 enrolled
Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)
Completed·—·Phase 2·NCT00215202·16 enrolled
Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma
Completed·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT01514526·17 enrolled
The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma
Completed·KKing's College Hospital NHS Trust·N/A·NCT05344027·35 enrolled
Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma
Completed·AAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia·Phase 3·NCT03723941·40 enrolled
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
Completed·CCorcept Therapeutics·Phase 1·NCT04373265·15 enrolled
Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
Completed·CCollaborative Group for Adrenocortical Carcinoma Treatment·Phase 3·NCT00094497·304 enrolled
Sunitinib in Refractory Adrenocortical Carcinoma
Completed·UUniversity of Wuerzburg·Phase 2·NCT00453895·39 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)